What’s new

• Won turnkey order worth ₹31.23 cr from Botswana Vaccine Institute.
• Contract covers design, supply, installation, testing, commissioning over 14 months.
• Order represents ~7% of FY26 revenue, ~5% of market cap; new disclosure.

Why it matters

This order materially boosts revenue visibility for the micro-cap and extends its geographical footprint into Africa. At ~7% of FY26 revenue, the order is significant relative to company scale and is a genuine surprise as there was no prior indication. It validates Fabtech's capability in international cleanroom projects.

What we’re watching

• Execution timeline of 14 months and any further orders from Botswana.
• Impact on order book and revenue guidance for FY27.
• Potential for more African contracts given this reference.

The full read

Fabtech Technologies has secured a ₹31.23 crore turnkey order from Botswana Vaccine Institute — its first African contract of this scale. It's a clean win. The deal runs 14 months, covering design through commissioning. At 7% of FY26 revenue and 5% of market cap, this is material for the micro-cap. More important: no prior filings hinted at this, making it a genuine surprise. The order validates Fabtech's international competitiveness and diversifies its geography beyond the Middle East and India. Execution is the next test; the open question is whether this opens the door for more African business.

Primary source: BSE · NSE